
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees is expected to continue raising capital to finance operations but has raised approximately $3.4 million net through ATM sales during Q1, improving cash position which ended at $3.3 million. With the potential new pipeline opportunity of Australian Chestnut extract and ongoing commercial initiatives for ARAKODA, the company may see increased product sales momentum and improved profitability in FY2026. However, risks to achieving these goals include balance sheet and liquidity risks, as well as clinical trial results and regulatory approvals for their product candidates.
Bears say
60 Degrees is a specialty pharmaceutical company with a focus on developing new therapies for infectious diseases. However, recent financials show a decline in product revenue and a growing cash deficit, indicating potential challenges in commercial and clinical developments. Additionally, risks such as failed clinical trials, dilutive capital raises, and lack of commercial success could impede the stock. Therefore, a Neutral rating is appropriate until there is more visibility on ARAKODA and tafenoquine's progress in the treatment of fungal, viral, and vector-borne diseases.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares